ArticleDiabetology & metabolic syndrome2025
Systematic validation of miR-503-5p abnormal expression in diabetic vascular complications: a meta-analysis and exploration of its targeted regulatory mechanism in retinopathy.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Longitudinal and Stability-Aware Analysis Reveals Treatment-Specific MicroRNA Response Signatures Following Immune-Reconstitution and B-Cell-Targeted Therapies in Multiple Sclerosis.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic vascular complications are major health concerns. MicroRNAs (miRNAs) are implicated in their pathogenesis. This study aimed to evaluate the abnormal expression of miR-503-5p in diabetic vascular complications and explore its regulatory mechanisms in diabetic retinopathy.
methodsStudies on miR-503-5p expression in diabetic vascular complications were selected from PubMed, Embase, Web of Science, Cochrane, and Scopus databases. Experimental validation was carried out utilizing human retinal pigment epithelial cells (ARPE-19) that were subjected to a high glucose (HG) environment. miR-503-5p expression, cell proliferation, apoptosis, inflammatory cytokines, and oxidative stress markers were measured.
resultsThe meta-analysis showed miR-503-5p was upregulated overall in diabetic vascular complications (SMD = 0.71, 95% CI: -2.21 to 3.64). Subgroup analysis showed that miR-503-5p expression was significantly increased in cell samples (SMD = 5.84, 95% CI: 2.40 to 9.27), and in major vascular complications (SMD = 2.89, 95% CI: 0.35 to 5.44). High miR-503-5p could distinguish diabetic retinopathy from healthy controls (AUC = 0.918, sensitivity = 81.2%, specificity = 92.7%). HG upregulated miR-503-5p in ARPE-19 cells. miR-503-5p inhibitor linked to increased proliferation, reduced apoptosis, and modulated inflammatory and oxidative stress responses.
conclusionsMiR-503-5p was significantly upregulated in diabetic vascular complications, particularly in cell samples and major vascular complications. MiR-503-5p may serve as a diagnostic biomarker for diabetic retinopathy. The elevated levels of miR-503-5p in ARPE-19 cells under high glucose conditions were associated with increased inflammation, oxidative stress, and apoptosis, as well as decreased cell proliferation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.